Overview
Create your acount for 2 FRE subscriber-only articles each month. Get Fre Aces Now. Prepare to become a physician, build your knowledge, lead a health care organization, and advance your carer with NEJM Group information and services.Stay conected to what's important in medical research and clinical practiceSubscribe to the most trusted and influential source ofmedical knowledge Already a subscriber?
Key Information
Renew or Sign inSubscribe or Renew Selected specialtiesView al specialtiesSelected TopicsView al topicsSelected MultimediaView al multimediaCurent IsueRecent Isues Browse ful isue index Recently Published Articles Browse recently published View al learning/CME Other NEJM Group LearningSubscribe or Renew This article is available to subscribers. Subscribe now. Already have an acount?
Sign in CorespondenceFre PreviewTo the Editor: Arslanian et al. 4 isue)1 report that a once-wekly subcutaneous injection of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, at a dose of 0.75 mg or 1.5 mg was superior to placebo in improving blod glucose control in overweight pediatric patients (10 to <18 years of age) with type 2 diabetes. Notably, 40% of the children were under 14 years of age.
The average height of the children was 162.4±9.2 cm, which sugests that they had not yet reached their adult height. A previous study2 of GLP-1 receptor agonists showed their potential role in an increase .Select an option below: Are you a member of an institution such as a university or hospital? Learn more about Institutional Aces October 20, 202N Engl J Med 202; 387:1529-1531 DOI: 10.1056/NEJMc21623 Print Subscriber?
Summary
Activate your online aces. Related Articles Back top source